Genome-wide screen identifies drug-induced regulation of the gene giant axonal neuropathy (Gan) in a mouse model of antiretroviral-induced painful peripheral neuropathy

Biological Research for Nursing

Volumn 11, Issue 1, 2009, Pages 7-16

  Dorsey, Susan G ^a   Leitch, Carmen C ^a   Renn, Cynthia L ^a   Lessans, Sherrie ^a   Smith, Barbara A ^a   Wang, Xiao M ^b   Dionne, Raymond A ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

^b NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

Author keywords

Chronic pain; Giant axonal neuropathy; Gigaxonin; HAART; HIV AIDS; Microarray; NRTI; Painful peripheral neuropathy

Indexed keywords

CYTOSKELETON PROTEIN; GAN PROTEIN, MOUSE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CHROMOSOME MAP; DISEASE MODEL; DNA MICROARRAY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MALE; MOUSE; NURSING RESEARCH; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PROTEIN MICROARRAY; TIME; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CHROMOSOME MAPPING; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED C57BL; NURSING RESEARCH; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMERASE CHAIN REACTION; PROTEIN ARRAY ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TIME FACTORS;

EID: 67949111159     PISSN: 10998004     EISSN: 15524175     Source Type: Journal    
DOI: 10.1177/1099800409332726     Document Type: Article

References (32)

1. Asbury, A.K., Gale, M.K., Cox, S.C., Baringer, J.R., & Berg, B.O. (1972). Giant axonal neuropathy-A unique case with segmental neurofilamentous masses. Acta Neuropathologica, 20, 237-247.
2. Berg, B.O., Rosenberg, S.H., & Asbury, A.K. (1972). Giant axonal neuropathy. Pediatrics, 49, 894-899.
3. Berger, A.R., Arezzo, J.C., Schaumburg, H.H., Skowron, G., Merigan, T., Bozette, S., et al. (1993). 20, 30 -dideoxycytidine (ddC) toxic neuropathy: A study of 52 patients. Neurology, 43, 358-362.
4. Bhangoo, S.K., Ren, D., Miller, R.J., Chan, D.M., Ripsch, M.S., Weiss, C., et al. (2007). CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy. Brain, Behavior, and Immunity, 21, 581-591.
5. Bomont, P., Cavalier, L., Blondeau, F., Hamida, C.B., Belal, S., Tazir, M., et al. (2000). The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. Nature Genetics, 26, 370-374.
6. Brinley, F.J., Pardo, C.A., & Verma, A. (2001). Human immunodeficiency virus and the peripheral nervous system workshop. Archives of Neurology, 58, 1561-1566.
7. Centers for Disease Control. (2008). HIV/AIDS in the United States (Revised August 2008). Retrieved August 29, 2008, from http://www.cdc.gov/hiv/ resources/factsheets/us.htm
8. Cornblath, D.R., & McArthur, J.C. (1988). Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology, 38, 794-796.
9. Dalakas, M.C. (2001). Peripheral neuropathy and antiviral drugs. Journal of the Peripheral Nervous System, 6, 14-20.
10. d'Arminio Monforte, A., Lepri, A.C., Rezza, G., Pexxotti, P., Antinori, A., Phillips, A.N., et al. (2000). Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral na»ve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Na»ve Patients. AIDS, 14, 499-507. (Pubitemid 30209692)
11. Ding, J., Allen, E., Wang, W., Valle, A., Wu, C., Nardine, T., et al. (2006). Gene targeting of GAN in mouse causes a toxic accumulation of microtubule-associated protein 8 and impaired retrograde axonal transport. Human Molecular Genetics, 15, 1451-1463.
12. Dorsey, S.G., & Morton, P.G. (2006). HIV peripheral neuropathy: Pathophysiology and clinical implications. AACN Clinical Issues: Advanced Practice in Acute and Critical Care, 17, 30-36.
13. Hall, H.I., Song, R., Rhodes, P., Prejean, J., An, Q., Lee, L.M., et al. (2008). Estimation of HIV incidence in the United States. JAMA, 300, 520-529.
14. Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., & Scherf, U. et al. (2003). Exploration, normalization and summaries of high density oligonucleotide array probe level data. Biostatistics, 4, 249-264.
15. Joseph, E.K., Chen, X., Khasar, S.G., & Levine, J.D. (2004). Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain, 107, 147-158.
16. McCarthy, B.G., Hsieh, S.T., Stocks, A., Hauer, P., Macko, C., Cornblath, D.R., et al. (1995). Cutaneous innervation in sensory neuropathies: Evaluation by skin biopsy. Neurology, 45, 1848-1855.
17. Moore, R.D., Wong, W.M., Keruly, J.C., & McArthur, J.C. (2000). Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS, 14, 273-278.
18. Moyle, G.J., & Sadler, M. (1998). Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management. Drug Safety: An International Journal of Medical Toxicology and Drug Experience, 19, 481-594.
19. Ouvrier, R.A. (1989). Giant axonal neuropathy. A review. Brain Development, 11, 207-214.
20. Polydefkis, M., Yiannoutsos, C.T., Cohen, B.A., Hollander, H., Schifitto, G., Clifford, D.B., et al. (2002). Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology, 58, 115-119.
21. Reiner, A., Yekutieli, D., & Benjamini, Y. (2003). Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics, 19, 368-375.
22. Schifitto, G., McDermott, M.P., McArthur, J.C., Marder, K., Sacktor, N., & Epstein, L. et al. (2002). Incidence of and risk factors for HIV-associated distal sensory neuropathy. Neurology, 58, 1764-1768.
23. Simpson, D.M. (2002). Selected peripheral neuropathies associated with human immunodeficiency virus infection and antiretroviral therapy. Journal of NeuroVirology, 8 (Suppl. 2). 33-41.
24. So, Y.T., Holtzman, D.M., Abrams, D.I., & Olney, R.K. (1988). Peripheral neuropathy associated with acquired immunodeficiency syndrome. Archives of Neurology, 45, 945-948.
25. Timmerman, V., De Jonghe, P., & Van Broeckhoven, C. (2000). Of giant axons and curly hair. Nature Genetics, 26, 254-255.
26. Unaids. (2007). AIDS epidemic update 2007. Retrieved August 29, 2008, from http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/ 2007/default.asp
27. Verma, A. (2001). Epidemiology and clinical features of HIV-1 associated neuropathies. Journal of the Peripheral Nervous System, 6, 8-13.
28. Walker, U.A. (2003). Update on mitochondrial toxicity: Where are we now ? Journal of HIV Therapy, 8, 32-35.
29. Wallace, V.C.J., Blackbeard, J., Segerdahl, A.R., Hasnie, F., Pheby, T., McMahon, S.B., et al. (2007). Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain, 130, 2688-2702.
30. White, A.J. (2001). Mitochondrial toxicity and HIV therapy. Sexually Transmitted Infections, 77, 158-173.
31. Wulff, E.A., Wang, A.K., & Simpson, D.M. (2000). HIV-associated peripheral neuropathy: Epidemiology, pathophysiology and treatment. Drugs, 59, 1251-1260.
32. Zimmerman, M. (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain, 16, 109-110.